Handelsavisen
prelaunch
Companies Healthcare HYFT.O
HY
HYFT.O NASDAQ Diversified Pharmaceuticals

MindWalk Holdings Corp

$1,39
Open in Charts → Attach watcher ⌖
USD
Set alert
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
64,9M USD
P/E
EV / Rev
Div yield
Op margin
-136,9 %
ROE
-128,0 %
Net margin
-123,3 %
Debt / equity
0,57
Beta
52w range
Volume
Day range
Prev close
$1,41
Open
Next earnings
Ex-dividend
TR 1Y
About

MindWalk Holdings Corp is a Canadian-based company operating in the pharmaceuticals and medical research industry, primarily generating revenue through the development and commercialization of digital therapeutics and related healthcare technologies.

Business. MindWalk Holdings Corp (HYFT.O) is a pharmaceutical company engaged in pharmaceuticals and medical research. The firm is headquartered in the United States and is primarily listed on the NASDAQ exchange. Specific details regarding operating segments and geographic revenue mix are not available.

Classification99 %
SectorHealth Care
Industry groupDiversified Pharmaceuticals
Generated · model-assisted
Sell-side consensus
BUY3 analysts
3 buy0 hold0 sell
Avg 12m price target4,33

Analyst recommendations

3 analysts · consensus Buy
Buy3
Hold0
Sell0
12-month price target
4,33
Consensus of sell-side coverage.
Upcoming events
— missing data
See all catalysts →

At a glance

Score
not yet scored
Valuation
valuation pending
Analysts
Buy
3 analysts · indicative
Ownership
UBS Financial Services, Inc.
largest disclosed fund holder
Profitability
-128,0 %
return on equity
Quality
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

0
  • No recent newsroom coverage mentioning HYFT.
  • Sector rotation

    Sector1D1Mvs mkt
    Materials+2,3 %+6,6 %+1,7 %
    Communication Services+2,2 %−5,5 %+1,7 %
    Energy+0,6 %+3,3 %+0,0 %
    Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
    Consumer Discretionary+0,4 %+7,7 %−0,2 %
    Information Technology+0,3 %+7,8 %−0,3 %
    Financials−0,3 %−2,8 %−0,9 %
    Consumer Staples−0,4 %+2,5 %−1,0 %
    Real Estate−0,7 %+10,9 %−1,3 %
    Industrials−1,9 %−3,1 %−2,5 %
    Utilities−1,9 %+28,2 %−2,5 %

    Developing storylines

    No tracked sagas currently linked to HYFT.O. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Macro
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
    • Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
    • Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
    • Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
    • Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR

    Pre-earnings brief

    — missing data

    Signals & dispatch

    peak dispatch · —

    Composite-score breakdown

    Synthesis

    Business

    MindWalk Holdings Corp (HYFT.O) is a pharmaceutical company engaged in pharmaceuticals and medical research. The firm is headquartered in the United States and is primarily listed on the NASDAQ exchange. Specific details regarding operating segments and geographic revenue mix are not available.

    Classification99 %
    SectorHealth Care
    Industry groupDiversified Pharmaceuticals
    AI synthesis
    GENERATED

    MindWalk Holdings Corp has a market capitalization of CAD 56.05 million and a price-to-book ratio of 2.37, indicating a premium valuation relative to its book value. The company's liquidity position is characterized as medium, with a current ratio of 2.08, suggesting it can cover its short-term liabilities with its current assets. However, the company's operating cash flow is negative at CAD -6.41 million, and its free cash flow is also negative at CAD -26.17 million, indicating a lack of cash generation from operations.

    Profitability metrics show that the company is not currently generating positive returns. The return on equity is -127.97%, and the return on assets is -68.03%, both significantly below industry norms for a profitable pharmaceutical company. The company's operating income is negative at CAD -33.56 million, and its net income is also negative at CAD -30.23 million, indicating a substantial loss-making position.

    The company's revenue is concentrated in a single business segment, as disclosed in its financial statements, with no significant geographic diversification reported. This lack of diversification may expose the company to higher operational and market risks if its primary product or service faces regulatory or market challenges.

    The company's growth trajectory is uncertain, with no clear indication of revenue growth in the current fiscal year. The operating income and net income have both declined, and the company has not provided specific guidance for the next fiscal year. The negative cash flows and lack of profitability raise concerns about the company's ability to sustain operations without additional financing.

    The risk assessment indicates a medium liquidity risk, with the company's net cash position being negative after accounting for total debt. The dilution risk is assessed as low, with no immediate pressure for share issuance or dilution. The company's debt-to-equity ratio of 0.57 suggests a moderate level of leverage, but the negative operating cash flow may limit its ability to service debt obligations.

    Recent events and filings do not indicate any significant changes in the company's strategic direction or financial position. The company has not disclosed any major product launches, partnerships, or regulatory approvals that could drive future revenue growth. Analysts have provided a mean price target of CAD 4.00, with a median price target of CAD 4.00, suggesting a potential upside from the current market price of CAD 1.20.

    Key takeaways
    • The company is currently unprofitable, with a negative return on equity and return on assets.
    • The company's liquidity position is medium, with a current ratio of 2.08, but it has negative operating and free cash flows.
    • The company's revenue is concentrated in a single business segment, with no significant geographic diversification.
    • Analysts have provided a mean price target of CAD 4.00, indicating a potential upside from the current market price.
    • The company's debt-to-equity ratio is 0.57, suggesting a moderate level of leverage.
    • "margin_outlook_rationale": "The company's operating and net margins are negative, indicating a lack of profitability and no clear improvement in the near term.",

    Bull / Bear case

    Generated · model-assisted
    — missing data

    In focus — financials by report

    Valuation

    Market price
    $1,39
    Market cap
    $56.1M
    Enterprise value
    $69.5M
    P/E
    Non-GAAP P/E
    EV / Revenue
    EV / Op income
    EV / OCF
    P / B
    2.4x
    P / Tangible book
    2.4x
    Tangible book
    $23.6M
    Net cash
    -$13.4M
    Current ratio
    2.1
    Debt / equity
    0.6
    ROA
    -68.0%
    ROE
    -1.3%
    Cash conversion
    21.0%
    CapEx / revenue
    -3.3%
    SBC / revenue
    Dilution ratio
    0.0%

    Revenue by segment

    Market share

    INDUSTRYSEGMENTCOMPANYHealthcareIndustryDiversified Pharmaceuticals1 042,4B node revenueMCK 38,7%COR 30,8%CAH 21,4%DB 3,4%REGN 1,4%BIIB 0,9%ZTS 0,9%GRFS 0,8%Other 1,7%
    Source: company disclosures · own-taxonomy revenue-covered setHYFT 0,0% · rank #26 of 40

    Business relationships

    — missing data

    Supply chain

    — missing data

    Peer comparison

    Peer comparison8 peers · vs HYFT · multiples and returns
    MC
    MCK
    Mckesson Corp
    $829,00
    102,9B USD
    P/E
    21,2x
    vs self
    Div yield
    0,4 %
    vs self
    ROE
    -219,2 %
    vs self
    CO
    COR
    Cencora Inc
    $312,00
    60,9B USD
    P/E
    36,4x
    vs self
    Div yield
    0,8 %
    vs self
    ROE
    45,7 %
    vs self
    CA
    CAH
    Cardinal Health Inc
    $235,33
    56,9B USD
    P/E
    36,7x
    vs self
    Div yield
    0,9 %
    vs self
    ROE
    -55,9 %
    vs self
    DB
    DB
    DB.V
    P/E
    vs self
    Div yield
    vs self
    ROE
    vs self
    RE
    REGN
    REGENERON PHARMACEUTICALS, INC.
    $758,42
    81,0B USD
    P/E
    15,5x
    vs self
    Div yield
    vs self
    ROE
    14,2 %
    vs self
    BI
    BIIB
    BIOGEN INC.
    $201,74
    29,6B USD
    P/E
    21,3x
    vs self
    Div yield
    vs self
    ROE
    7,5 %
    vs self
    ZT
    ZTS
    Zoetis Inc
    P/E
    vs self
    Div yield
    vs self
    ROE
    vs self
    GR
    GRFS
    Grifols SA
    $7,84
    P/E
    vs self
    Div yield
    vs self
    ROE
    vs self

    Market position

    Stress test

    — missing data

    Predictor forecast

    Next quarternear-term
    Earnings · next quarterconf 45 %
    EPS
    Consensus EPS
    -0,31
    Predicted surprise
    -0,08
    Beat probability
    45 %
    Analysts
    3
    Other metrics
    Revenue
    no estimate
    Segment revenue
    no estimate
    Margin
    no estimate
    Segment margin
    no estimate
    revision ratio 0,00 · as of 2026-07-17 · Earnings Surprise V1
    Period note: consensus is not fiscal-period-aligned at source — read as consensus vs the last reported actual, not a calibrated same-quarter surprise.
    Full fiscal year~1 year ahead
    Full fiscal year · our forecast vs guidance vs consensus
    MetricOur forecastGuidanceConsensus
    EPSno estimateno estimate-0,31
    Revenueno estimateno estimate15,9M CAD
    Operating incomeno estimateno estimate-13,9M CAD
    Full-year consensus mean (period as reported by source) · consensus in CAD. Company-level full-year forecast and management guidance are not yet modelled at scale — shown as "no estimate", never inferred.
    Probabilistic model output — not investment advice. · generated 2026-08-04

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Consensus distribution

    sell-side coverage
    Recommendation distribution3 analysts
    Strong buy0
    Buy3
    Hold0
    Sell0
    Strong sell0
    12-month price target$4,33 · Median $5,00
    Low $3,00High $5,00
    Operating income · consensus-13,9M CAD
    EPS surprise
    −196,7 %
    reported vs consensus · miss
    Revenue surprise
    +54,6 %
    reported vs consensus · beat

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    Low$3,00
    Mean$4,33
    Median$5,00
    High$5,00
    Spot$1,39
    +211.7 %implied to mean12-month sell-side price targets · ▲ spot

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskLow
    Liquidity riskMedium
    Filing-based flags
    • Net cash is negative after subtracting total debt.

    Benchmarks vs cohort

    Op Margin-136,9 %Bottom quartile
    Net Margin-123,3 %Below median
    ROE-128,0 %Bottom quartile
    Capex / Rev-3,3 %Below median
    D/E0,57Bottom quartile
    Cash Conv0,21Below median

    Corporate actions / M&A

    — missing data

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    — missing data

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Market data
    • Market data cache
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    How metrics are computed
    • Return On Equity
      net_income / total_equity
    • Price To Book
      market_price / (adjusted_book_value / shares_outstanding_diluted)
    • Dilution Ratio
      (shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
    • Market Price
      input from market-data provider (delayed close or quote-shim mid)
    • Market Cap
      market_price * shares_outstanding_diluted
    • Ev To Revenue
      enterprise_value / revenue
    Source documents
    • MindWalk Holdings Corp Market data — financials · 2026-05-28
    • MindWalk Holdings Corp Market data — analyst estimates · 2026-05-28

    Ownership & reference

    Top holders

    • UBS Financial Services, Inc.Investment Managers · as of 2026-03-310,00 %$0M
    • Geode Capital Management, L.L.C.Investment Managers · as of 2026-03-310,00 %$0M
    • Morgan Stanley Smith Barney LLCInvestment Managers · as of 2026-03-310,00 %$0M

    Leadership

    • Jennifer Lynne BathPresident, Chief Executive Officer, Director

    Insider activity

    — missing data

    Short positioning

    952.6Kshares short+11.6% vs prior
    4.37days to cover
    53.9%short of daily vol
    33.9Kfails-to-deliver
    as of 2026-07-15 · short-interest report (free)

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    HYFT.OCanonical
    NASDAQ · USD

    Intel & risk

    PredictorBeat prob45 %Surprise-0,08Full forecast →
    peak dispatch · —
    OSINT findings
    Dilution riskLow
    Liquidity riskMedium
    Net cash is negative after subtracting total debt.

    Evidence & claims

    From filings & derived data
    — missing data

    The Thread

    Everything we know, in order
    2026-07-22 00:00 UTCTRANSCRIPTEarnings call — Q3 2026
    2026-07-22EVENTQ2 2026 earnings (expected) estimated date
    2026-06-30 03:38 UTCEARNINGSUpcomingForecast: earnings_forecast (90d)
    2026-06-12FILING6-K filing →
    2026-06-10FILING6-K filing →
    2026-06-02FILING6-K filing →
    2026-05-27FILING6-K filing →
    2026-05-18FILING6-K filing →
    2026-03-31FILING6-K filing →
    2026-03-23FILING6-K filing →
    2026-03-12FILING6-K filing →
    2026-03-12FILING6-K filing →
    2026-03-06FILING6-K filing →
    2026-03-02FILING6-K filing →
    2026-01-27FILING6-K filing →
    The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage